Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT02358889 is registered in ClinicalTrials.gov with Iconic Therapeutics, Inc. as lead sponsor.

NCT NCT02358889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02358889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Lead sponsor
Iconic Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
September 30, 2016
Enrollment
88 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, choroidal neovascularization